Table 2.
Pharmacological FAK Inhibitors.
| Inhibitor | Company | Type and Target | Clinical Trial* | Identifiers/References |
|---|---|---|---|---|
| TAE226 | Novartis | ATP-competitive kinase inhibitor; FAK and Pyk2 | Preclinical | None/(Halder et al. 2007; Liu et al. 2007) |
| PF-573,228 | Pfizer | ATP-competitive kinase inhibitor; FAK | Preclinical | None/(Slack-Davis et al. 2007) |
| GSK-2256098 | GlaxoSmithKline | ATP-competitive kinase inhibitor; FAK | Phase I | NCT01138033 and NCT00996671/(Bottsford-Miller 2011) |
| PND-1186 (VS-4718) | Poniard (Verastem) | ATP-competitive kinase inhibitor; FAK | Phase I | NCT01849744/(Tanjoni et al. 2010; Walsh et al. 2010) |
| PF-562,271 (VS-6062) | Pfizer (Verastem) | ATP-competitive kinase inhibitor; FAK and Pyk2 | Phase I | NCT00666926/(Shapiro et al. 2014; Stokes et al. 2011) |
| PF-04554878 (VS-6063) | Pfizer (Verastem) | Unknown | Phase II | NCT02004028 and NCT01778803/None |
| Y15 | Cure FAKtor | Protein scaffold inhibitor; FAK | Preclinical | None/(Golubovskaya et al. 2012) |
| Y11 | Cure FAKtor | Protein scaffold inhibitor; FAK | Preclinical | None/(Hochwald et al. 2009) |
*
Clinical trial identifier is available at ClinicalTrials.gov.